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similar in the low-CNI and standard CNI arms. The postrandomization incidence of biopsy-proven acute rejection was 11.7%, 8.1% and 7.9% in the CNI-free, low-CNI and standard CNI groups, respectively (CNI-free versus standard CNI, P ¼ 0.27; low-CNI versus standard CNI, P ¼ 1.00). Adverse events led to study drug discontinuation in 28.7%, 15.5% and 15.2% of CNI-free, low-CNI and standard CNI patients, respectively. Conclusions. Everolimus initiation with CNI withdrawal at Month 3 after kidney transplantation achieves a significant improvement in renal function at 12 months, with a similar rate of acute rejection.
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I N T R O D U C T I O N
Mammalian target of rapamycin (mTOR) inhibitors block cytokine-dependent lymphocyte proliferation by interrupting the mTOR signal transduction pathway [1] , a mechanism distinct from that of calcineurin inhibitors (CNIs). The efficacy of mTOR inhibitors, coupled with an absence of the nephrotoxic effect, which is characteristic of CNI therapy, has prompted an extensive series of trials investigating the optimal use of this class of drug in kidney transplant recipients [2, 3] . Entirely CNI-free mTOR inhibitor-based immunosuppression is generally not favoured due to an increased risk of graft rejection [4] . Instead, recent trials have focused on use of mTOR inhibitors to facilitate CNI withdrawal or low-dose CNI regimens [3, 5] . A number of randomized studies have explored conversion from CNI therapy to using the mTOR inhibitors everolimus [6] [7] [8] [9] [10] [11] or sirolimus [12] [13] [14] [15] [16] [17] [18] at various times posttransplant, either pre-emptively or in response to deteriorating renal function and other CNI-related complications. It has been shown that if CNI withdrawal is delayed until after the first year post-transplant the renal benefit is limited [6, 14, 19] , and there is a growing consensus that conversion from CNI to an mTOR inhibitor should be undertaken pre-emptively by Month 6 [3] , before irreversible tubulointerstitial damage has developed [20] .
The best time point to convert kidney transplant patients from a CNI-based regimen to an mTOR inhibitor-based regimen, however, has not been conclusively determined. In the SMART [17] and CENTRAL [11] studies, conversion from cyclosporine (CsA) at Days 10-24 and Week 7 post-transplant, respectively, was associated with improved renal function but a high rate of discontinuations due to the high concentrations of mTOR inhibitor required during this early post-transplant period. Very early switch from CNI to an mTOR inhibitor based, CNI-free regimen may also risk increased graft rejection [10, 11] . Mixed results have been reported for slightly later conversion [8, 15, 18] .
Regimens in which everolimus has been used to support low-dose CNI have been investigated in randomized trials of kidney [21, 22] and liver [23, 24] transplant recipients. The A2309 study in kidney transplant patients found that inclusion of everolimus from time of transplant allowed up to 60% reduction in CNI exposure with no loss of efficacy and similar renal function over a 2-year follow-up period [22] .
HERAKLES was a prospective, randomized, multicentre trial in which de novo kidney transplant patients were randomized at Month 3 post-transplant to remain on standard CNI-based therapy or convert to everolimus with a CNI-free regimen. A third treatment arm was included, in which everolimus at a lower exposure range was administered with reduced CNI. The primary objective of the study was to demonstrate superior renal function with a CNI-free everolimus regimen compared with standard CNI therapy.
M A T E R I A L S A N D M E T H O D S
Study design and conduct HERAKLES was a multicentre, open-label, prospective, randomized, parallel-group, 12-month study undertaken at 18 transplant centres in Germany during 2007-11 (ClinicalTrials.gov-NCT00514514). Three months after kidney transplantation, patients were randomized to continue a standard-exposure CNI-based regimen or convert to everolimus within a CNI-free regimen or everolimus with low-exposure CNI. The study was undertaken in accordance with the principles outlined in the Declaration of Helsinki. Written informed consent was obtained from all patients following approval from the institutional review board at each participating centre.
Patient population
Patients aged 18-70 years who received a deceased, livingrelated or living-unrelated kidney transplant were eligible for enrolment. At the screening visit prior to transplantation, the key exclusion criteria were as follows: more than one previous kidney transplant, receipt of a multiorgan transplant (e.g. kidney and pancreas) or previous transplant with any other organ, a non-heart beating donor, a donor aged <5 years or >70 years, previous graft loss due to immunological reasons in the first year after transplantation, receipt of an ABO incompatible transplant, historical or current (last 3 months) peak panel reactive antibodies >25%, thrombocytopaenia (platelets <75 000/ mm 3 ), with an absolute neutrophil count of <1500/mm 3 or leukopaenia (leukocytes <2500/mm 3 ), or haemoglobin (Hb) <6 g/ dL. At the visit prior to randomization, additional inclusion criteria were an immunosuppressive regimen comprising entericcoated mycophenolate sodium (EC-MPS) (target dose 1440 mg/day if tolerated, minimum dose 720 mg/day), CsA and corticosteroids, and serum creatinine level 3.0 mg/dL (265 mmol/L), while key additional exclusion criteria were graft loss, changes to the immunosuppressive regimen prior to randomization due to immunologic reasons, severe rejection (Banff grade !II), recurrent acute rejection or steroid-resistant acute rejection prior to randomization, thrombocytopaenia with an absolute neutrophil count of <1500/mm 3 or leukopaenia, Hb <6 g/dL, proteinuria >1 g/day, current dialysis dependency and intractable immunosuppressant complications or side effects (e.g. severe gastrointestinal adverse events).
Immunosuppression and concomitant medication
Patients meeting the additional inclusion and exclusion criteria at the visit prior to randomization were stratified according to type of donor (deceased or living) and randomized at Month 3 in a 1:1:1 ratio using a central, validated, automated system with the patient's treatment group notified to the centre on the day of randomization by fax.
All patients received induction with basiliximab (Simulect V R , Novartis Pharmaceuticals AG, Basel, Switzerland, 20 mg on Days 0 and 4). Maintenance immunosuppression to the point of randomization comprised CsA (Neoral (R), Novartis Pharmaceuticals AG) with EC-MPS (Myfortic (R), Novartis Pharmaceuticals AG, 1440 mg) and steroids according to local protocol. In the standard CNI group, this regimen remained unchanged with the CsA dose adjusted according to predefined exposure targets (Supplementary data, Table S1 ). In the CNI-free group, everolimus was initiated at a dose of 1.5 mg on the day of randomization with CsA dose reduced by 50%. On the following day, everolimus was increased to 3 mg and CsA was discontinued. Everolimus dose was then adjusted to target C 0 5-10 ng/mL thereafter. EC-MPS was continued at a dose of 1440 mg/day. In the low-CNI group, EC-MPS was discontinued and everolimus was started at a dose of 1.5 mg on the day of randomization with CsA dose unchanged, then on the following day CsA dose was adjusted to pre-defined targets approximately 50% lower than in the standard CNI arm (Supplementary data, Table S1 ) [25] . Everolimus dose was adjusted to target C 0 3-8 ng/mL. All patients continued to receive corticosteroids according to local practice, at a dose of at least 5 mg prednisolone or equivalent continued to Month 12.
Prophylactic treatment for cytomegalovirus (CMV) as per local practice was strongly recommended for recipient-negative donor-positive transplants. All patients could receive prophylactic treatment for pneumocystis pneumonia according to local practice.
Study variables
The primary variable for assessment of renal function was change in estimated glomerular filtration rate (eGFR) calculated according to the Nankivell formula [26] from randomization (Month 3) to Month 12. Secondary efficacy variables at Month 12 included eGFR using the Cockcroft-Gault formula [27] and the Modification of Diet in Renal Disease (MDRD) formula [28] , occurrence of biopsy-proven acute rejection (BPAR), graft loss or death, and occurrence of treatment failure (defined as composite endpoint of biopsy-proven acute rejection (BPAR), graft loss, death, loss to follow-up, study discontinuation due to lack of efficacy or adverse events). Safety variables included the incidence and severity of (serious) adverse events, adverse events leading to premature discontinuation, and infections (particularly clinically apparent CMV infection), tumours and proteinuria.
Statistical analysis
The sample size calculation estimated that 133 patients per treatment group would have 90% power to detect a difference in mean eGFR between the standard CNI and CNI-free groups of 8 mL/min [standard deviation (SD) 20 mL/min], derived from published data [29, 30] with two-sided significance level a ¼ 5%. Enrolment of 180 patients per treatment group was planned to allow for non-randomization of approximately 20% of enrolled patients.
The intent-to-treat (ITT) population consisted of all randomized patients who received at least one dose of any immunosuppressive therapy after randomization and provided at least one post-baseline eGFR value (Nankivell) . The per protocol population included all ITT patients who completed the Month 12 study visit on their randomized study regimen without any major protocol violations. The safety population consisted of all transplanted patients who received at least one dose of any immunosuppressive medication after study entry, regardless of whether the patient was randomized.
The primary variable, change in eGFR (Nankivell) from randomization to Month 12, was compared between the CNI-free and standard CNI groups by analysis of covariance (ANCOVA) with treatment, centre and donor type as factors and eGFR at randomization as covariate. The ITT population was used for the primary analysis. If a patient discontinued the study prematurely after randomization, the last observation carried forward (LOCF) method was used if at least one post-randomization value for eGFR was available. Raw and adjusted (least square) means were used as point estimates for all pair-wise treatment comparisons, with two-sided 95% confidence intervals (CI) and P-values provided for the null hypothesis of no treatment difference. For superiority testing, least-squared means were compared with a two-sample test. The significance level was 5% (two-sided). As a sensitivity analysis, eGFR estimated by the Cockcroft-Gault method and the MDRD method was analysed in the same manner. Comparisons of eGFR at Month 12 in the CNI-free and the standard CNI groups versus the low-CNI treatment arm were exploratory. Efficacy event rates were estimated using the Kaplan-Meier method.
R E S U L T S

Patient population
In total, 802 patients were enrolled into the study, of whom 499 patients (62.2%) met the eligibility criteria at Month 3 posttransplant and were randomized ( Figure 1 ). Two patients did not receive the allocated study drug after randomization, such that the ITT and safety populations included 497 patients (171 CNI-free, 161 low-CNI, 165 standard CNI) ( Figure 1 ). Premature study discontinuation occurred in 61/171 (35.7%) in the CNI-free group, 38/162 (23.5%) in the low-CNI group and 39/166 (23.5%) of patients in the standard CNI group. The three treatment groups were well matched (Table 1) .
Immunosuppression
Mean (SD) everolimus C 0 over the period from randomization to Month 12 was 6.3 (1.8) ng/mL in the CNI-free group and 6.2 (3.9) ng/mL in the low-CNI arm. The proportion of patients in the CNI-free group with everolimus C 0 below target (5-10 ng/ mL) was 48.3% (73/151) at Month 4 (i.e. 1 month postrandomization), declining slightly to 40 
In the standard CNI group, mean (SD) CsA C 0 was 141 (32) ng/mL from randomization to Month 12, and was within target range throughout the study (Figure 2 ). In the low-CNI arm, mean CsA trough concentration from randomization to Month 12 was 100 (28) ng/mL, which was !30.0% above the target range (50-75 ng/mL) throughout ( Figure 2 ). The proportion of patients in the low-CNI group with CsA trough concentration within target range after randomization was 41.2, 32.1, 41.2 and 38.1%, respectively, at Months 4, 6, 9 and 12, with !45.0% above target at each visit. The mean dose of EC-MPS between randomization and Month 12 was similar in the CNI-free group (974 mg/day) and the standard CNI group (937 mg/day). The randomized study drug regimen was discontinued in 25.7% (44/171), 19.3% (31/161) and 14.5% (24/165) of patients in the CNI-free, low-CNI and standard CNI groups, respectively. In the CNI-free cohort, 117 patients (68.4%) remained on everolimus at the last study visit; CsA and tacrolimus were introduced in 13 and 11 patients, respectively. In the low-CNI arm, everolimus was continued in 120 patients (74.5%).
Graft function
Observed mean (SD) eGFR (Nankivell) at the time of randomization was 66.0 (15.6) mL/min/1.73 m 2 in the CNI-free group, 63.1 (14.9) mL/min/1.73 m 2 in the low-CNI group and 61.9 (15.0) mL/min/1.73 m 2 in the standard CNI group (Figure 3) . At Month 12, the corresponding values were 71.7 (19.4) mL/min/1.73 m 2 , 63.5 (19.6) mL/min/1.73 m 2 and 62.5 (17.0) mL/min/1.73 m 2 (P < 0.001 for the CNI-free group versus the low-CNI and standard CNI group) (Figure 3) .
The primary efficacy variable, change in eGFR (Nankivell) from randomization to Month 12, was significantly greater in the CNI-free arm versus the standard-therapy group, with a difference of 5.6 mL/min/1.73 m 2 (95% CI 2.8-8.3 mL/min/1.73 m 2 ) (P < 0.001) (LS mean values) ( Table 2 ). This difference was confirmed when eGFR was calculated by the Cockcroft-Gault and MDRD formulae ( Table 2 ). The change in eGFR between the CNI-free and low-CNI groups was also significant, using any formula. The low-CNI group did not show any renal advantage versus the standard CNI arm overall ( Table 2) .
The primary efficacy variable was also assessed in the per protocol population, in which all patients remained on study drug and were followed to Month 12 (standard CNI n ¼ 106, CNI-free n ¼ 89, low-CNI n ¼ 107). Results did not differ substantially from the ITT population (Table 2) . Only a small proportion of patients in the per protocol population remained within the CsA target range at all (or all but one) post-baseline study visits (standard CNI n ¼ 43, low-CNI n ¼ 33). In this subgroup, the change in eGFR for the low-CNI versus the standard CNI group was 1.7 mL/min/1.73 m 2 (95% CI À3.8 to 7.2 mL/ min/1.73 m 2 )(P ¼ 0.54). Urine protein >1 g/day occurred in 11.3% (17/171), 10.0% (14/161) and 9.7% (14/165), of patients in the CNI-free, low-CNI and standard CNI groups, respectively, at one or more study visits after randomization. At the Month 12 visit, the incidence was 6.5, 4.5 and 0%, respectively. The median change in urine protein from randomization to Month 12 was 7, 2 and À26 mg/day in the CNI-free, low-CNI and standard CNI groups, respectively.
Immunosuppressive efficacy
In the period from randomization to Month 12, there were no significant differences in the incidence of the composite efficacy endpoint or in any individual component (Table 3 ). The incidence of BPAR in this period was 11.7% in the CNI-free group, 8.1% in the low-CNI group and 7.9% in the standard CNI group (P ¼ 0.27 standard CNI versus CNI-free; P ¼ 1.00 standard CNI versus low CNI). Kaplan-Meier estimates confirmed this similarly (Figure 4 ). There were numerically more mild (Grade IA) episodes of BPAR in the CNI-free cohort (Table 3) .
There were four graft losses, two in the CNI-free group (one due to chronic rejection, one due to infection), one in the low- 
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CNI group (acute rejection) and one in the standard CNI group (insufficient diuresis with hydropic decompensation). Death occurred in two patients in the CNI-free group (sepsis and progressive meningoencephalitis), two in the low-CNI group (cardiac failure in both cases) and three in the standard CNI arm (heart failure, bronchial carcinoma and accidental death).
Safety
The overall rate of adverse events after randomization was similar in all three treatment groups (Table 4) . Diarrhoea and aphthous stomatitis occurred more frequently in the CNI-free group than the other treatment arms. CMV infection occurred (Nankivell) according to treatment group (ITT population). Rdn, randomization. *P < 0.001 for CNI-free versus low CNI and versus standard CNI; **P ¼ 0.007 for CNI-free versus low CNI and P < 0.001 for CNI-free versus standard CNI. Values for the three treatment groups are offset laterally at each time point to allow for better visualization. .0% of patients in the CNI-free and low-CNI groups, respectively, compared with 10.3% in the standard CNI arm. Wound healing complications affected two, one and two patients in the CNI-free, low-CNI and standard CNI arms, respectively. Neoplasms occurred in 14, 6 and 13 patients in the CNI-free, low-CNI and standard CNI groups, respectively, the most frequent of which were skin papilloma (CNI-free n ¼ 2, standard CNI n ¼ 3) and basal cell carcinoma (low-CNI n ¼ 1, standard CNI n ¼ 3).
The incidence of adverse events with a suspected relation to study drug was higher in the CNI-free and low-CNI groups after randomization versus the standard CNI group (Table 4) . The most frequent adverse events with a suspected relation to study drug were leukopaenia (CNI-free n ¼ 28, low-CNI n ¼ 12, standard CNI n ¼ 15), aphthous stomatitis (n ¼ 31, n ¼ 14 and n ¼ 1), diarrhoea (n ¼ 17, n ¼ 2 and n ¼ 6), urinary tract infection (n ¼ 18, n ¼ 19 and n ¼ 20), nasopharyngitis (n ¼ 7, n ¼ 9 and n ¼ 8) and hypercholesterolaemia (n ¼ 7, n ¼ 13 and n ¼ 1). Serious adverse events overall, or with a suspected relation to study drug, occurred at a similar frequency in all treatment groups (Table 4) .
Adverse events led to study drug discontinuation in 49 CNIfree patients (28.7%), 25 low-CNI patients (15.5%) and 25 standard CNI patients (15.2%). The most frequent adverse events leading to discontinuation in the CNI-free group were graft rejection (n ¼ 8), graft failure (n ¼ 3), proteinuria (n ¼ 4) and aphthous stomatitis (n ¼ 3). In the low-CNI group, the most frequent was rejection (n ¼ À5), and in the standard CNI group the most frequent were rejection (n ¼ 3) and increased serum creatinine (n ¼ 5).
Laboratory results at Month 12 showed mean values for liver enzymes (AST and ALT) to be highest, and urea to be lowest, in the CNI-free group (Supplementary data, Table S2 ). Levels of AST !3 times the upper level of normal were reported in three, BPAR, graft loss, death, loss to follow-up, study discontinuation due to lack of efficacy or adverse events, or conversion to another regimen.
zero and four patients in the CNI-free, low-CNI and standard CNI groups, respectively; for ALT the numbers were six, three and four patients. The mean leukocyte count was 7.0 Â 10 9 /L in the CNI-free group, 7.8 Â 10 9 /L in the low-CNI group and 8.0 Â 10 9 /L in the standard CNI group (Table 2) , with leukopaenia ( 2 Â 10 9 /L) in seven, one and eight patients, respectively. Mean values for haemoglobin, blood glucose and platelet count were similar between groups. Mean blood pressure at Month 12 was 129/78 mmHg in the CNI-free group, 135/ 81 mmHg in the low-CNI arm and 133/80 mmHg in the standard CNI group. Use of statin therapy, erythropoietin and antihypertensive medication showed no marked differences between the three treatment groups (Supplementary data, Table S3 ).
D I S C U S S I O N
A series of randomized trials has shown that early adoption of everolimus-based CNI-sparing regimens can improve longterm graft function, albeit with a higher risk of mild BPAR reported in several studies where CNI therapy has been withdrawn entirely [31] . The optimal strategy for CNI minimization has been widely discussed in the literature [3, 32, 33] but to date no randomized trial has directly compared everolimus with CNI withdrawal, everolimus with ongoing low-dose CNI or standard CNI therapy following kidney transplantation. This provided the rationale for the current three-arm study.
Results showed that starting everolimus therapy with CNI withdrawal 3 months after kidney transplantation achieved a significant and clinically relevant improvement in renal function by 1 year post-transplant, with no increase in BPAR. Mean eGFR increased by approximately 5 mL/min/1.73 m 2 after randomization in the CNI-free group while remaining largely unchanged with standard CNI therapy. A slight imbalance in mean eGFR between the groups at baseline was accounted for in the primary analysis of change in eGFR to Month 12. This finding confirms those of previous studies in which kidney transplant patients were switched from CNI to everolimus before Month 6 post-transplant [8, 10, 11] (Supplementary data, Table S4 ). We are aware that the approximate rate of study discontinuation was higher in the CNI-free arm; however, when the primary endpoint analyses were repeated only in the subpopulation of patients who were treated as per protocol throughout, outcomes were similar to the ITT population, confirming the benefit on renal function. Importantly, this is the first trial to combine a significant renal benefit with no significant increase in BPAR after switch to an everolimus-based CNI-free regimen. Grade IA BPAR was numerically more frequent in the CNI-free arm, while Grade II BPAR occurred in only one CNIfree patient but in four standard CNI patients; overall, the rate of BPAR was not significantly different, which confirms the immunosuppressive efficacy of the everolimus-based regimen. It is relevant to compare these results to the recent ZEUS study, which switched patients to everolimus from Month 4.5 [8] . In Table 4 . Adverse events and serious adverse events occurring between randomization and Month 12, n (%) (safety population) ZEUS, there was a significant increase in mild BPAR following conversion that led to a higher total incidence of BPAR overall in the CNI-free group [8] . Both the ZEUS and HERAKLES study protocols selected similar patient populations, with the same immunosuppressive regimens. Actual drug exposure levels and doses were also comparable. Analysing both studies together, it seems likely that any change in the baseline immunosuppressive regimen may result in a slightly higher frequency of rejection if trough levels are not carefully monitored. Ideally, a meta-analysis of similar randomized trials will provide more robust data than any single trial alone. The clinical relevance of these predominantly mild rejections needs to be determined in long-term follow-up of larger study populations. Everolimus with reduced CNI matched the immunosuppressive efficacy of the standard CNI regimen, consistent with other randomized trials in which this regimen was started immediately post-transplant [21] or from Month 1 [34] . However, everolimus with reduced CNI did not improve renal function versus standard therapy. Suboptimal adherence to CNI exposure targets after the start of everolimus may have influenced the results: at least 45% of patients in the low-CNI group had CsA trough concentration above the maximum level at each study visit after randomization. It is important to note that everolimus with concomitant CsA can potentiate CNI-related nephrotoxicity [35] if CsA levels are too high [36] . This does not fully account for the lack of renal benefit, however. Among the subpopulation who had a CsA trough level within target range at all (or all but one) post-randomization visits, the change in eGFR from randomization to Month 12 tended to be better (1.7 mL/min/1.73 m 2 ) in the low-CNI arm versus the standard CNI cohort, and also compared with the À0.9 mL/min/1.73 m 2 difference between the two groups overall. Previously, in the A2309 trial, in which 823 kidney transplant patients were randomized to everolimus with reduced CNI or to standard CNI from the time of transplant, renal function did not differ significantly between regimens [21] , whereas another smaller randomized trial reported renal superiority after switch to everolimus with reduced CsA from Month 1 onwards [34] . Again, the findings from this large trial provide additional evidence for future meta-analyses on this topic.
Urine protein >1 g/day occurred at a similar frequency in all treatment groups although, as anticipated given the known association between mTOR inhibitors and proteinuria [37] , only the standard CNI group showed a decrease in mean urine protein after randomization. Similar to the ZEUS trial [8] and other mTOR conversion trials [10, 11, 17] , early conversion in selected stable patients seems to create no major safety signal with regard to proteinuria.
The pattern of adverse events was as expected in each treatment group. CMV infection occurred in approximately half as many patients in the CNI-free and low-CNI groups as the standard CNI arm, consistent with the literature [38] . Adverse events with a suspected relation to everolimus were more frequent in the two everolimus-containing groups. This was probably partly due to the fact that all patients had 3 months' treatment with CsA prior to randomization, and any adverse event first reported before Month 3 under CsA was not included in the post-randomization adverse event data. The rate of serious adverse events with a suspected relation to study was comparable between groups, but more patients in the CNI-free group discontinued study drug due to adverse events than in the other two arms, possibly due to a tendency to switch back to conventional therapy from the investigational regimen in the event of rejection or safety events. Laboratory data did not indicate any safety concerns. Liver enzyme levels were higher in the CNI-free group, but abnormal levels were rare in all groups.
Certain characteristics of the HERAKLES study should be considered. The trial had the advantage of a large study population, and was the first randomized trial of everolimus to undertake a three-way comparison of CNI-free or low-CNI therapy versus a standard CNI regimen. However, patients received CsA, whereas tacrolimus is the dominant CNI therapy. Additionally, it would have been helpful to capture data on donor-specific antibodies (DSAs), but at the time the study protocol was developed DSAs were not widely measured. The core study ended at 1-year post-transplant, and further follow-up is needed to determine whether the sustained renal benefit of CNI therapy reported in the CENTRAL [39] and ZEUS [40] studies at 3 and 5 years, respectively, is also observed in this population. Lastly, it should be noted that the selection criteria for HERAKLES excluded patients at high immunological risk, and the finding that BPAR rates were comparable across treatment groups would need to be confirmed for higher-risk individuals.
In conclusion, everolimus initiation with abrupt CNI withdrawal at Month 3 after kidney transplantation achieves a significant improvement in 12-month renal function with a similar rate of BPAR, in patients at low or standard immunological risk. Introduction of everolimus with continued lowexposure CNI also maintains immunosuppressive efficacy but without a significant renal benefit. These results suggest no advantage in delaying introduction of everolimus beyond 3 months post-transplant.
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